Eton Pharmaceuticals Relaunches HEMANGEOL®

Eton Pharmaceuticals announced the relaunch of HEMANGEOL® (propranolol) Oral Solution, the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease. The company has integrated the Eton Cares patient support program, offering $0 co-pay for eligible commercially insured patients and expanded patient assistance programs. HEMANGEOL will be exclusively distributed through Anovo Specialty Pharmacy to streamline patient access and therapy initiation. The drug is indicated for proliferating infantile hemangioma requiring systemic therapy, typically initiated between five weeks to five months of age. Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases and currently offers ten commercial products, with four additional candidates in late-stage development.